Clinical Trials for Brain Tumor

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent or progressive IDH-wildtype glioblastoma after radiotherapy, no more than two prior relapses, and a surgically accessible tumor are randomized to receive or not receive presurgical troriluzole before resection. All patients receive postoperative troriluzole, an investigational riluzole prodrug intended to reduce glutamate release and promote clearance.

ClinicalTrials.gov ID: NCT06552260

Phase 1b/2 Trial of Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with cutaneous melanoma brain metastases progressing after immunotherapy and at least one untreated, measurable brain lesion receive defactinib (a FAK/PYK2 inhibitor) plus avutometinib (a RAF/MEK clamp). Patients with BRAF V600E/K-mutant disease also receive encorafenib, a BRAF inhibitor.

ClinicalTrials.gov ID: NCT06194929

A Dose Escalation Study Using Eflornithine (DFMO) and AMXT 1501 Followed by a Randomized Controlled Trial of DFMO With or Without AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls patients diagnosed by age 21 with relapsed or refractory high-risk neuroblastoma, ETMR, ATRT, Ewing sarcoma, or osteosarcoma, or newly diagnosed DIPG after radiation. Patients receive oral eflornithine (DFMO), an ornithine decarboxylase inhibitor that blocks polyamine synthesis, with or without AMXT 1501, an investigational polyamine-uptake inhibitor; the neuroblastoma cohort is randomized between the two regimens.

ClinicalTrials.gov ID: NCT06465199

Safety and Efficacy of Ivonescimab and Chemotherapy Plus Stereotactic Radiosurgery (SRS) in the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with squamous or nonsquamous NSCLC, at least one SRS-eligible brain metastasis (1.0–3.5 cm), and ECOG performance status 0–1 receive chemotherapy plus ivonescimab, a bispecific antibody targeting PD-1 and VEGF-A, followed by three-fraction SRS. The study evaluates a tolerable ivonescimab dose and 3-month intracranial disease control.

ClinicalTrials.gov ID: NCT07535463

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed or refractory HER2-altered advanced cancers after progression on or intolerance of their last systemic therapy receive oral IAM1363, an investigational irreversible HER2 inhibitor designed to penetrate the brain. Patients with brain metastases may enroll unless they need immediate local therapy.

ClinicalTrials.gov ID: NCT06253871

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with 1-8 intact (unresected), non-brainstem brain metastases from solid tumors (such as NSCLC, melanoma, breast, renal, or GI cancers), good performance status, and no prior brain radiotherapy are randomized to receive either single-session stereotactic radiosurgery (SRS) or fractionated SRS (three sessions). Both approaches are non-invasive, high-precision outpatient radiotherapy options for brain metastases.

ClinicalTrials.gov ID: NCT06500455

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, advanced or unresectable TP53-mutated or TP53-loss triple-negative breast cancer, platinum-resistant high-grade serous ovarian, primary peritoneal or fallopian-tube cancer, or recurrent serous endometrial cancer receive oral AO-252 monotherapy. AO-252 is an investigational inhibitor of TACC3 protein–protein interactions.

ClinicalTrials.gov ID: NCT06136884

A Multi-Center Phase I Dose Escalation Study of Avutometinib, a RAF/MEK Clamp, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway Alterations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients aged 3–30 years with recurrent or refractory solid tumors, including CNS tumors, harboring activating MAPK pathway alterations receive oral avutometinib monotherapy; eligible patients also include those with specified NF1-associated tumors or progressive optic pathway gliomas. Avutometinib is a RAF/MEK clamp that inhibits MEK and stabilizes an inactive RAF–MEK complex to suppress ERK signaling.

ClinicalTrials.gov ID: NCT06104488

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Patients older than 15 years with recurrent IDH1/2-mutant WHO grade 2–4 diffuse glioma after radiation and/or chemotherapy receive oral zotiraciclib monotherapy; prior bevacizumab for tumor treatment is excluded. Zotiraciclib is an investigational multikinase inhibitor that targets CDK9 and other kinases.

ClinicalTrials.gov ID: NCT05588141

A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent glioblastoma and good performance status receive VBI-1901, a therapeutic vaccine containing cytomegalovirus gB and pp65 antigens designed to stimulate antitumor immunity, with GM-CSF or AS01B. The randomized portion enrolls patients with first-recurrence, IDH-wildtype disease and compares VBI-1901 plus GM-CSF with single-agent carmustine or lomustine.

ClinicalTrials.gov ID: NCT03382977